降脂化瘀汤联合水飞蓟宾葡甲胺片对痰瘀互结型非酒精性脂肪肝患者血清ALT、AST、GGT水平及血脂代谢的影响

丁麟; 蔡新吉; 王巍; 王秀艳

doi:10.3969/j.issn.1671-038X.2018.07.03

降脂化瘀汤联合水飞蓟宾葡甲胺片对痰瘀互结型非酒精性脂肪肝患者血清ALT、AST、GGT水平及血脂代谢的影响

- 济南军区总医院中医科, 山东济南 250031

详细信息

作者简介:
丁麟,男,硕士,住院医师,研究方向:主要从事肿瘤的中西医结合治疗工作

通讯作者: 丁麟,E-mail:dingling7832@163.com

中图分类号: R575.5

收稿日期: 2018-04-02

Influences of Jiangzhi Huayu decoction and silibin meglumine tablets on serum ALT, AST, GGT levels and blood lipid metabolism in patients with phlegm and silting stasis type non alcohol fatty liver disease

- Department of Traditional Chinese Medicine, General Hospital of Jinan Military Area, Ji'nan 250031, China

More Information

Corresponding author: DING Lin, E-mail: dingling7832@163.com

Received Date: 02 April 2018

摘要

摘要: [目的]探讨降脂化瘀汤联合水飞蓟宾葡甲胺片对痰瘀互结型非酒精性脂肪肝患者血清ALT、AST、GGT水平及血脂代谢的影响。[方法]选取我院2016年2月~2017年9月收治的106例痰瘀互结型非酒精性脂肪肝患者作为研究对象，按随机数字表法均分为治疗组（n=53）和对照组（n=53）。2组均给予基础治疗，在此基础上对照组服用水飞蓟宾葡甲胺片，治疗组在对照组基础上联合应用降脂化瘀汤进行治疗。比较2组患者临床疗效、中医证候积分、血清谷丙转氨酶（ALT）、谷草转氨酶（AST）、谷氨酰转肽酶（GGT）水平、血脂代谢状况及不良反应发生情况。[结果]治疗组总有效率92.45%较对照组的71.70%高（P<0.05）；治疗后2组中医症候积分均较治疗前低（P<0.05），且治疗组均较对照组低（P<0.05）；治疗后2组血清ALT、AST、GGT水平均较治疗前低（P<0.05），且治疗组较对照组低（P<0.05）；治疗后2组总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（LDL-C）水平均较治疗前低（P<0.05），低密度脂蛋白胆固醇（HDL-C）水平较治疗前高（P<0.05），且2组比较差异有统计学意义（P<0.05），且治疗组TC、TG、LDL-C水平低于对照组（P<0.05），HDL-C水平高于对照组（P<0.05）；治疗组与对照组不良反应发生率比较差异无统计学意义（P>0.05）。[结论]痰瘀互结型非酒精性脂肪肝患者实施降脂化瘀汤与水飞蓟宾葡甲胺片联合治疗，可显著提高临床疗效，明显下调血清ALT、AST、GGT水平，有效改善血脂代谢状况，且安全性较高。
- 降脂化瘀汤 /
- 水飞蓟宾葡甲胺片 /
- 痰瘀互结型 /
- 非酒精性脂肪肝 /
- 血脂代谢
Abstract: [Objective] To investigate the influences of Jiangzhi Huayu Decoction and Silibin Meglumine Tablets on serum ALT, AST, GGT levels and blood lipid metabolism in patients with phlegm and silting stasis type non alcohol fatty liver disease.[Methods] 106 patients with phlegm and silting stasis type non alcohol fatty liver disease who were admitted to our hospital from February 2016 to September 2017 were randomly divided into treatment group (n=53) and control group (n=53).The two groups were given basic treatment, on this basis, the control group took Silibin Meglumine Tablets, the treatment group was combined with Jiangzhi Huayu Decoction on the basis of the control group.The clinical efficacy, TCM syndrome scores, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transpeptidase (GGT) levels, blood lipid metabolism, and incidence rate of adverse reactions were compared between the two groups.[Results] The total effective rate in the treatment group was 92.45%, which was higher than 71.70% in the control group (P<0.05); after treatment, the TCM symptom scores of the two groups were lower than that before treatment (P<0.05), and the treatment group was lower than the control group (P<0.05); serum ALT, AST and GGT levels after treatment were lower than that before treatment (P<0.05), and the treatment group was lower than the control group (P<0.05); after treatment, the levels of total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (LDL-C) were lower than that before treatment (P<0.05), and low-density lipoprotein cholesterol (HDL-C) level was higher than that before treatment (P<0.05), and the differences between the two groups were statistically significant (P<0.05), the level of TC, TG and LDL-C in the treatment group was lower than that of the control group (P<0.05), and the level of HDL-C was higher than that of the control group (P<0.05); there was no significant difference in the incidence rate of adverse reactions between the treatment group and the control group (P>0.05).[Conclusion] The combination therapy of Jiangzhi Huayu Decoction and Silibin Meglumine Tablets in patients with phlegm and silting stasis type non alcohol fatty liver disease can significantly improve the clinical efficacy, significantly reduce the levels of serum ALT, AST and GGT, and effectively improve blood lipid metabolism, and the security is high.
- Jiangzhi Huayu decoction /
- silibin meglumine tablets /
- phlegm and silting stasis type /
- non alcohol fatty liver disease /
- blood lipid metabolism

HTML全文

参考文献(19)

[1]	付凤侠.安络化纤丸联合水飞蓟宾胶囊治疗非酒精性脂肪肝43例临床观察[J].海南医学, 2014, 25(8):1171-1172.
[2]	刘秀林, 付京云, 刘丽花, 等.柴荷化痰活血方治疗非酒精性脂肪肝50例临床疗效观察[J].北京中医药, 2015, 34(7):560-562.
[3]	蔡岳, 张赤志, 王学书.行气化痰法治疗非酒精性脂肪肝的临床观察[J].中医药导报, 2015, 21(17):83-85.
[4]	中华医学会肝脏病学会分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].中华内科杂志.2010, 49(3):275-278.
[5]	国家技术监督局.中医临床诊疗术语——疾病部分(续)[J].成都中医药大学学报, 2003, 26(2):62-63.
[6]	国家中医药管理局.中医病证诊断疗效标准[M].南京:南京大学出版社, 1994:216-219.
[7]	王康, 郑通美.化痰祛瘀方加减治疗痰瘀互结型酒精性脂肪肝病疗效观察[J].辽宁中医杂志, 2014, 41(1):118-119.
[8]	Younossi Z M, Koenig A B, Abdelatif D, et al.Global epidemiology of nonalcoholic fatty liver disease-Metaanalytic assessment of prevalence, incidence, and outcomes[J].Hepatology, 2016, 64(1):73-73.
[9]	Chalasani N, Younossi Z, Lavine J E, et al.The Diagnosis and Management of Nonalcoholic Fatty Liver Disease:Practice Guidance from the American Association for the Study of Liver Diseases.[J].Am J Gastroenterol, 2017, 67(6):811-811.
[10]	许秋玉, 孙晓娜, 许向前, 等.化痰消脂汤治疗非酒精性脂肪肝痰瘀互结证临床研究[J].中医学报, 2015, 30(9):1346-1347.
[11]	陈晓顶, 范录平, 张有超, 等.化滞柔肝颗粒对非酒精性脂肪肝脂联素、IL-6、TNF-α水平的影响[J].中国生化药物杂志, 2017, 37(2):65-67.
[12]	龙云铸, 李丹, 潭英征, 等.恩替卡韦联合水飞蓟宾葡甲胺片治疗HBeAg阳性乙型肝炎的远期疗效研究[J].河北医药, 2017, 39(12):1836-1837.
[13]	卢广余.恩替卡韦联合水飞蓟宾葡甲胺治疗乙肝合并非酒精性脂肪肝52例及对病毒载量等指标的影响[J].中国药业, 2015, 24(24):84-86.
[14]	姜德民, 王一强, 张玉香.非酒精性脂肪肝的中医药研究进展[J].西部中医药, 2016, 29(6):160-162.
[15]	吴娅妮, 周佩娟, 陈轶, 等.降脂理肝汤治疗非酒精性脂肪肝临床疗效分析[J].辽宁中医药大学学报, 2014, 16(6):19-21.
[16]	张广宏, 仇军, 许剑婕.自拟化瘀降脂汤联合辛伐他汀对高血脂症患者血脂及肝功能指标的影响[J].现代中西医结合杂志, 2017, 26(2):179-181.
[17]	邢增智, 陈旺, 曾宇.泽泻的化学成分与药理作用研究进展[J].中医药导报, 2017, 23(15):75-78.
[18]	舒文将, 姚昕利, 陈宗游, 等.中药柴胡的药理研究与临床应用[J].广西科学院学报, 2017, 33(4):268-273.
[19]	尉广飞, 李翠, 刘谦, 等.干燥前水洗对丹参活性成分的影响[J].中草药, 2015, 46(16):2467-2470.